FDA Refuses New Drug Application for Zogenix’s Fintepla (ZX008)
The U.S. Food and Drug Administration (FDA) refused the New Drug Application (NDA) for Fintepla (ZX008), Zogenix‘s investigational anti-seizure therapy for patients with Dravet syndrome. According to statements from the FDA, the Refusal to File (RTF) letter was issued because the NDA submitted by Zogenix…